Project Grant R01CA303477
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $701K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- The National Cancer Institute awarded $694,929 to Vanderbilt University Medical Center on July 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to translate MR cytometry imaging into a clinical tool for cancer detection and diagnosis. MR cytometry is a diffusion MRI-based imaging technique that non-invasively measures mean cell size in vivo. The award funds an academic-industrial partnership among Vanderbilt University Medical Center, the University of Washington...
- The National Cancer Institute awarded Vanderbilt University Medical Center $603,714 on June 18, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an enhanced visualization and navigation system that improves surgical accuracy during endoscopic treatment of upper tract urothelial carcinoma. Current endoscopic tumor ablation relies on surgeons mentally constructing three-dimensional maps of branched renal anatomy from two-dimensional preoperative imaging, a...
- The National Cancer Institute awarded Vanderbilt University Medical Center $449,969 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop novel biomarkers for diagnosing malignant pleural effusion using extracellular vesicles and non-vesicular particles derived from pleural fluid. Malignant pleural effusion affects approximately 200,000 individuals annually in the United States, with lung cancer as the most common source. Current cytologic examination...
- The National Cancer Institute awarded Yale University $519,592 on June 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to validate deep learning-derived MRI imaging biomarkers for risk stratification in localized prostate cancer. The project develops and validates quantitative MRI biomarkers using deep learning to identify patients at highest risk for prostate cancer recurrence and to support treatment selection. The research addresses limitations of current...
- The National Cancer Institute awarded the University of Florida $632,670 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop transformer-based vision-language models for renal mass diagnosis and management through AI-enhanced decision support systems. The award funds development of segmentation algorithms and vision-language models trained on imaging data from the University of Florida Health Integrated Data Repository and public datasets to...
- The National Cancer Institute awarded Vanderbilt University Medical Center $543,816 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to validate the molecular origin of APT-weighted imaging in tumors. The recipient will develop and apply Chemical Exchange Saturation Transfer (CEST) editing techniques to separate amide proton transfer (APT) and nuclear Overhauser effect (NOE) signals from amine CEST, clarifying the true source of APT-weighted...
- The National Cancer Institute awarded the University of California, Davis $409,141 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop contrast-enhanced perfusion CT imaging as an alternative to current liver radioembolization workup procedures. The project addresses imaging optimization for selective internal radiation therapy (SIRT), a catheter-based treatment for liver cancer using radioactive yttrium-90 microspheres. Current clinical practice...
- The National Institutes of Health National Cancer Institute awarded Albert Einstein College of Medicine $431,970 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to refine and validate an MRI-based imaging technique for detecting tumor microenvironment of metastasis (TMEM) doorways in breast cancer. The award funds development of TMEM doorway activity-MRI (TDAM), a dynamic contrast-enhanced MRI method designed to measure vascular opening events...
- The National Cancer Institute awarded Emory University $639,077 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop rapid quantitative amide proton transfer-weighted (APTW) magnetic resonance imaging for brain tumor characterization at 3 Tesla field strength. The work addresses clinical challenges in chemical exchange saturation transfer (CEST) MRI by refining the quasi-steady-state (QUASS) algorithm to reconstruct equilibrium CEST signals...
- The National Cancer Institute awarded Cedars-Sinai Medical Center $709,677 on June 5, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop quantitative multiparametric PSMA PET-MR imaging to optimize treatment planning for partial gland ablation of prostate cancer. The project addresses limitations in multiparametric MRI for prostate cancer mapping, which fails to detect more than 30 percent of high-grade tumors and most low-grade tumors. The funded work...